Actinic Keratosis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Medication, Therapies, NICE Approvals and Companies by DelveInsight

Globe and Mail

23-05-2025

Actinic Keratosis companies are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, among others.
(Albany, USA) DelveInsight's " Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Actinic Keratosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Actinic Keratosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Actinic Keratosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Actinic Keratosis market.
Some facts of the Actinic Keratosis Market Report are:
According to DelveInsight, Actinic Keratosis market size is expected to grow at a decent CAGR by 2034.
Leading Actinic Keratosis companies working in the market are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, Amgen Inc., Cangene Corporation, BD and Bosch Healthcare Solutions GmbH among others.
Key Actinic Keratosis Therapies expected to launch in the market are AVX001, VDA-1102, and others.
In February 2025, Almirall, S.A announced results of a Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis
In November 2024, Vidac Pharma has secured €600,000 ($645,651) in additional funding to advance the clinical development of its two lead cancer candidates. Announced during the company's recent shareholder meeting, this funding from existing investors will allow Vidac to initiate a new Phase IIb trial for its lead candidate, VDA-1102 (tuvatexib) ointment. The hexokinase 2 inhibitor is being studied for its potential in treating advanced cases of actinic keratosis, a skin condition that may progress to cutaneous squamous cell carcinoma (SCC).
In May 2024, TORQUR announced results of a Randomized Phase 2 Proof-of-Concept Study to Evaluate the Efficacy and Safety of Topical Bimiralisib Application in Participants Suffering From Actinic Keratosis on the Face and/or Scalp and/or Back of Hands Over a 2 and 4-week Treatment Period
Additionally, the launch of new therapies such as VDA-1102, SR-T100 Gel, and other innovative topical treatments is anticipated to enhance treatment outcomes and broaden market prospects.
According to Chetty P et al., the prevalence of AK varies from 6–60%, depending on age, phototype and other predisposing risk factors (most notably immunosuppressed status, outdoor workers), and is increasing
In a study conducted by Schaefer et al., it was found that the standardized prevalence of AK from dermatological examinations was 2.7%; the rate increased with age (11.5% in the group 60-70 years) and was higher for men (3.9%) than for women (1.5%)
Actinic Keratosis Overview
Actinic keratosis (AK) is a common skin condition characterized by rough, scaly patches that develop due to long-term exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Actinic keratosis usually occurs on areas of the body that receive the most sun exposure, such as the face, scalp, ears, neck, and hands.
These lesions are usually small, red, or flesh-colored, with a rough texture resembling sandpaper. While actinic keratosis is not cancerous in itself, it is considered a precancerous condition, as a small percentage of Actinic keratosis may progress to squamous cell carcinoma, a type of skin cancer.
It is important to have Actinic keratosis evaluated and treated by a healthcare professional. Treatment options include topical creams, cryotherapy (freezing), chemical peels, photodynamic therapy, or surgical removal. Prevention is crucial, and measures such as sun protection (using sunscreen, wearing protective clothing, and seeking shade), regular skin examinations, and avoiding artificial UV radiation can help reduce the risk of developing actinic keratosis. Early detection and treatment of Actinic keratosis can significantly lower the risk of skin cancer.
Actinic Keratosis Market
The Actinic Keratosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Actinic Keratosis market trends by analyzing the impact of current Actinic Keratosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Actinic Keratosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Actinic Keratosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Actinic Keratosis market in 7MM is expected to witness a major change in the study period 2020-2034.
Actinic Keratosis Epidemiology
The Actinic Keratosis epidemiology section provides insights into the historical and current Actinic Keratosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Actinic Keratosis market report also provides the diagnosed patient pool, trends, and assumptions.
Actinic Keratosis Drugs Uptake
This section focuses on the uptake rate of the potential Actinic Keratosis drugs recently launched in the Actinic Keratosis market or expected to be launched in 2020-2034. The analysis covers the Actinic Keratosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Actinic Keratosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Actinic Keratosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Actinic Keratosis Pipeline Development Activities
The Actinic Keratosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Actinic Keratosis key players involved in developing targeted therapeutics.
Learn more about the emerging Actinic Keratosis Market drivers and barriers @ Actinic Keratosis Market Dynamics
Actinic Keratosis Therapeutics Assessment
Major key companies are working proactively in the Actinic Keratosis Therapeutics market to develop novel therapies which will drive the Actinic Keratosis treatment markets in the upcoming years are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, Amgen Inc., Cangene Corporation, BD and Bosch Healthcare Solutions GmbH among others.
Actinic Keratosis Therapies and Companies
Actinic Keratosis Report Key Insights
1. Actinic Keratosis Patient Population
2. Actinic Keratosis Market Size and Trends
3. Key Cross Competition in the Actinic Keratosis Market
4. Actinic Keratosis Market Dynamics (Key Drivers and Barriers)
5. Actinic Keratosis Market Opportunities
6. Actinic Keratosis Therapeutic Approaches
7. Actinic Keratosis Pipeline Analysis
8. Actinic Keratosis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Actinic Keratosis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Actinic Keratosis Competitive Intelligence Analysis
4. Actinic Keratosis Market Overview at a Glance
5. Actinic Keratosis Disease Background and Overview
6. Actinic Keratosis Patient Journey
7. Actinic Keratosis Epidemiology and Patient Population
8. Actinic Keratosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Actinic Keratosis Unmet Needs
10. Key Endpoints of Actinic Keratosis Treatment
11. Actinic Keratosis Marketed Products
12. Actinic Keratosis Emerging Therapies
13. Actinic Keratosis Seven Major Market Analysis
14. Attribute Analysis
15. Actinic Keratosis Market Outlook (7 major markets)
16. Actinic Keratosis Access and Reimbursement Overview
17. KOL Views on the Actinic Keratosis Market
18. Actinic Keratosis Market Drivers
19. Actinic Keratosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: [phone]
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage